Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2021-03-26 5:07 pm Unchanged |
2021-03-25 | 13D | Graybug Vision, Inc. GRAY |
ORBIMED ADVISORS LLC | 297,382 19.800% |
0 (Unchanged) |
Filing History |
| 2021-03-25 4:15 pm Purchase |
2021-03-23 | 13G | X4 Pharmaceuticals, Inc. XFOR |
ORBIMED ADVISORS LLC | 1,835,993 7.600% |
587,000 (+47.00%) |
Filing History |
| 2021-03-19 6:06 pm Sale |
2021-03-17 | 13D | ORIC Pharmaceuticals, Inc. ORIC |
ORBIMED ADVISORS LLC | 2,467,292 6.800% |
-298,425 (-10.79%) |
Filing History |
| 2021-03-03 6:50 pm Sale |
2021-03-01 | 13D | SpringWorks Therapeutics, Inc. SWTX |
ORBIMED ADVISORS LLC | 6,186,307 12.600% |
-1,220,000 (-16.47%) |
Filing History |
| 2021-03-01 6:13 pm Purchase |
2021-02-17 | 13D | Decibel Therapeutics, Inc. DBTX |
ORBIMED ADVISORS LLC | 4,061,774 16.700% |
4,061,774 (New Position) |
Filing History |
| 2021-03-01 6:09 pm Unchanged |
2020-12-31 | 13G | Kala Pharmaceuticals, Inc. KALA |
ORBIMED ADVISORS LLC | 188,568 8.410% |
0 (Unchanged) |
Filing History |
| 2021-02-25 7:41 pm Sale |
2021-02-24 | 13D | Xtant Medical Holdings, Inc. XTNT |
ORBIMED ADVISORS LLC | 72,803,072 93.600% |
-7,309 (-0.01%) |
Filing History |
| 2021-02-22 6:31 pm Purchase |
2021-02-09 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 3,791,204 15.100% |
3,791,204 (New Position) |
Filing History |
| 2021-02-22 3:47 pm Purchase |
2021-02-05 | 13D | Gemini Therapeutics, Inc. GMTX |
ORBIMED ADVISORS LLC | 582,622 12.900% |
582,622 (New Position) |
Filing History |
| 2021-02-18 9:48 pm Purchase |
2021-02-12 | 13D | RESTORBIO INC TORC |
ORBIMED ADVISORS LLC | 5,933,314 18.900% |
420,299 (+7.62%) |
Filing History |
| 2021-02-17 5:08 pm Purchase |
2021-02-17 | 13D | Corvus Pharmaceuticals, Inc. CRVS |
ORBIMED ADVISORS LLC | 8,053,298 21.980% |
1,285,714 (+19.00%) |
Filing History |
| 2021-02-12 5:13 pm Purchase |
2020-12-31 | 13G | Xenon Pharmaceuticals Inc. XENE |
ORBIMED ADVISORS LLC | 1,711,305 4.890% |
1,076,493 (+169.58%) |
Filing History |
| 2021-02-12 5:12 pm Purchase |
2020-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN |
ORBIMED ADVISORS LLC | 325,960 6.900% |
325,960 (New Position) |
Filing History |
| 2021-02-12 5:10 pm Purchase |
2020-12-31 | 13G | Theravance Biopharma, Inc. TBPH |
ORBIMED ADVISORS LLC | 5,544,212 8.670% |
5,544,212 (New Position) |
Filing History |
| 2021-02-12 5:08 pm Purchase |
2020-12-31 | 13G | Strongbridge Biopharma plc SBBP |
ORBIMED ADVISORS LLC | 2,986,869 4.440% |
2,986,869 (New Position) |
Filing History |
| 2021-02-12 5:07 pm Sale |
2020-12-31 | 13G | Prothena Corporation plc PRTA |
ORBIMED ADVISORS LLC | 1,485,458 3.720% |
-802,981 (-35.09%) |
Filing History |
| 2021-02-12 5:05 pm Purchase |
2020-12-31 | 13G | Otonomy, Inc. OTIC |
ORBIMED ADVISORS LLC | 2,480,800 5.140% |
1,083,233 (+77.51%) |
Filing History |
| 2021-02-12 5:04 pm Sale |
2020-12-31 | 13G | OBSEVA SA COM OBSVF |
ORBIMED ADVISORS LLC | 0 0.000% |
-2,605,531 (Position Closed) |
Filing History |
| 2021-02-12 5:00 pm Purchase |
2020-12-31 | 13G | Mereo BioPharma Group plc MREO |
ORBIMED ADVISORS LLC | 4,518,356 6.660% |
4,518,356 (New Position) |
Filing History |
| 2021-02-12 4:59 pm Purchase |
2020-12-31 | 13G | MeiraGTx Holdings plc MGTX |
ORBIMED ADVISORS LLC | 3,969,425 9.140% |
520,605 (+15.10%) |
Filing History |